Cargando...
Triheptanoin: First Approval
Triheptanoin (Dojolvi™), a synthetic medium-chain triglyceride, is being developed by Ultragenyx Pharmaceutical as a pharmaceutical-grade anaplerotic compound for use in the treatment of inherited metabolic disorders. In June 2020, triheptanoin received its first regulatory approval, in the USA, for...
Gardado en:
| Publicado en: | Drugs |
|---|---|
| Autor Principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Springer International Publishing
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7575481/ https://ncbi.nlm.nih.gov/pubmed/32897506 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01399-5 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|